SCHEMBL25322921

SCHEMBL25322921

COc1ccc(OC)c2c1sc1n[nH]c(=S)n12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP2 Q9UGN5 7/20 1.00
▸ TNKS2 Q9H2K2 4/20 1.00
▸ PARP10 Q53GL7 3/20 0.54
▸ PARP15 Q460N3 3/20 0.54
▸ TNKS O95271 1/20 0.54
▸ PARP1 P09874 1/20 0.54
▸ PARP6 Q2NL67 1/20 0.54
▸ PARP14 Q460N5 1/20 0.54
▸ TIPARP Q7Z3E1 1/20 0.54
▸ PARP16 Q8N5Y8 1/20 0.54
▸ PARP12 Q9H0J9 1/20 0.54
▸ PARP11 Q9NR21 1/20 0.54
▸ PARP4 Q9UKK3 1/20 0.54
▸ PARP3 Q9Y6F1 1/20 0.54
▸ ALDH1A1 P00352 6/20 0.40
▸ KDM4E B2RXH2 4/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ PLK1 P53350 1/20 0.39
▸ APOBEC3G Q9HC16 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25322731 0.70 PARP2 (1.00) PARP2TNKS2PARP10PARP15TNKS
SCHEMBL25325363 0.65 PARP2 (1.00) PARP2TNKS2PARP10PARP15TNKS
SCHEMBL25323518 0.64 PARP2 (1.00) PARP2TNKS2PARP10PARP15TNKS
SCHEMBL25322173 0.62 PARP2 (1.00) PARP2TNKS2PARP10PARP15TNKS
SCHEMBL8978546 0.60 KDM4E (0.68) ALDH1A1KDM4EKMT2AHSD17B10APOBEC3G
SCHEMBL25324132 0.59 PARP2 (0.74) PARP2TNKS2PARP10PARP15TNKS
SCHEMBL10720450 0.58 PARP2 (0.41) PARP2TNKS2PARP10PARP15TNKS
SCHEMBL8978521 0.57 KDM4E (1.00) ALDH1A1KDM4EKMT2AHSD17B10APOBEC3G
SCHEMBL25034534 0.55 KDM4E (0.66) PARP2TNKS2ALDH1A1KDM4EKMT2A
SCHEMBL30939182 0.53 TNKS2 (0.36) PARP2TNKS2ALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250177359-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS OULUN YLIOPISTO (FI) 2025-06-05 — — US disclosed
EP-4469046-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS Oulun Yliopisto (FI) 2024-12-04 — — EP disclosed
WO-2023144450-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS OULUN YLIOPISTO (FI) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250177359-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS NAMPT, NADK, NQO1 PARP2 15/4885TNKS2 29/4885PARP10 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback